
    
      The primary objective of this study is to evaluate the progression-free survival (PFS) in
      participants with platinum-refractory or platinum-resistant advanced ovarian cancer when
      treated with the monoclonal antibody Olaratumab in combination with liposomal doxorubicin
      versus liposomal doxorubicin alone.
    
  